Navigation Links
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
Date:6/24/2009

PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822.

Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 .

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group."

Please contact:

Dr Fintan Walton, CEO
PharmaVentures Ltd
+44 (0) 1865 784 187

About PharmaVentures Ltd
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored advisory and transaction services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television show www.pharmatelevision.com. Now in its 16th year PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

For further information about PharmaVentures Ltd please contact:
Lisa Holloway
Marketing
+44 (0) 1865 784 177

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2572184.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
2. Online Career Site Assists Academia in Its Reach
3. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
4. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
5. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
6. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
7. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
8. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
9. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
10. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
11. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016   ... an SNNLive Video Interview with Dr. Nader Pourhassan ... a biotechnology company focused on the clinical development and ... and prevention of HIV infection, according to the company,s ... was recorded on Tuesday, June 7 th , 2016, ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... (PRWEB) , ... June 22, 2016 , ... ... at placing a spotlight on immigrant achievements and contributions to North Texas and ... most important contributors from the immigrant community to the civic and economic vitality ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):